Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen

To conduct meta-analyses of randomized trials of aromatase inhibitors (AIs) compared with tamoxifen either as initial monotherapy (cohort 1) or after 2 to 3 years of tamoxifen (cohort 2). Data submitted to the Early Breast Cancer Trialists' Collaborative Group were used in separate meta-analyse...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Journal of clinical oncology Ročník 28; číslo 3; s. 509
Hlavní autoři:	Dowsett, Mitch, Cuzick, Jack, Ingle, Jim, Coates, Alan, Forbes, John, Bliss, Judith, Buyse, Marc, Baum, Michael, Buzdar, Aman, Colleoni, Marco, Coombes, Charles, Snowdon, Claire, Gnant, Michael, Jakesz, Raimund, Kaufmann, Manfred, Boccardo, Francesco, Godwin, Jon, Davies, Christina, Peto, Richard
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 20.01.2010
Témata:	Aged Antineoplastic Agents - therapeutic use Aromatase Inhibitors - therapeutic use Breast Neoplasms - drug therapy Breast Neoplasms - surgery Chemotherapy, Adjuvant Female Follow-Up Studies Humans Middle Aged Randomized Controlled Trials as Topic Tamoxifen - therapeutic use
ISSN:	1527-7755, 1527-7755
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Abstract	To conduct meta-analyses of randomized trials of aromatase inhibitors (AIs) compared with tamoxifen either as initial monotherapy (cohort 1) or after 2 to 3 years of tamoxifen (cohort 2). Data submitted to the Early Breast Cancer Trialists' Collaborative Group were used in separate meta-analyses of two cohorts. Primary analyses involve postmenopausal women with tumors reported to be estrogen receptor positive. Log-rank P values are two-sided. Cohort 1 comprised 9,856 patients with a mean of 5.8 years of follow-up. At 5 years, AI therapy was associated with an absolute 2.9% (SE = 0.7%) decrease in recurrence (9.6% for AI v 12.6% for tamoxifen; 2P < .00001) and a nonsignificant absolute 1.1% (SE = 0.5%) decrease in breast cancer mortality (4.8% for AI v 5.9% for tamoxifen; 2P = .1). Cohort 2 comprised 9,015 patients with a mean of 3.9 years of follow-up. At 3 years from treatment divergence (ie, approximately 5 years after starting hormonal treatment), AI therapy was associated with an absolute 3.1% (SE = 0.6%) decrease in recurrence (5.0% for AI v 8.1% for tamoxifen since divergence; 2P < .00001) and an absolute 0.7% (SE = 0.3%) decrease in breast cancer mortality (1.7% for AI v 2.4% for tamoxifen since divergence; 2P = .02). There was no convincing heterogeneity in the proportional recurrence reduction with respect to age, nodal status, tumor grade, or progesterone receptor status and no indication of an increase in nonbreast deaths with AIs in either cohort. CONCLUSION AIs produce significantly lower recurrence rates compared with tamoxifen, either as initial monotherapy or after 2 to 3 years of tamoxifen. Additional follow-up will provide clearer information on long-term survival.
AbstractList	To conduct meta-analyses of randomized trials of aromatase inhibitors (AIs) compared with tamoxifen either as initial monotherapy (cohort 1) or after 2 to 3 years of tamoxifen (cohort 2). Data submitted to the Early Breast Cancer Trialists' Collaborative Group were used in separate meta-analyses of two cohorts. Primary analyses involve postmenopausal women with tumors reported to be estrogen receptor positive. Log-rank P values are two-sided. Cohort 1 comprised 9,856 patients with a mean of 5.8 years of follow-up. At 5 years, AI therapy was associated with an absolute 2.9% (SE = 0.7%) decrease in recurrence (9.6% for AI v 12.6% for tamoxifen; 2P < .00001) and a nonsignificant absolute 1.1% (SE = 0.5%) decrease in breast cancer mortality (4.8% for AI v 5.9% for tamoxifen; 2P = .1). Cohort 2 comprised 9,015 patients with a mean of 3.9 years of follow-up. At 3 years from treatment divergence (ie, approximately 5 years after starting hormonal treatment), AI therapy was associated with an absolute 3.1% (SE = 0.6%) decrease in recurrence (5.0% for AI v 8.1% for tamoxifen since divergence; 2P < .00001) and an absolute 0.7% (SE = 0.3%) decrease in breast cancer mortality (1.7% for AI v 2.4% for tamoxifen since divergence; 2P = .02). There was no convincing heterogeneity in the proportional recurrence reduction with respect to age, nodal status, tumor grade, or progesterone receptor status and no indication of an increase in nonbreast deaths with AIs in either cohort. CONCLUSION AIs produce significantly lower recurrence rates compared with tamoxifen, either as initial monotherapy or after 2 to 3 years of tamoxifen. Additional follow-up will provide clearer information on long-term survival. To conduct meta-analyses of randomized trials of aromatase inhibitors (AIs) compared with tamoxifen either as initial monotherapy (cohort 1) or after 2 to 3 years of tamoxifen (cohort 2).PURPOSETo conduct meta-analyses of randomized trials of aromatase inhibitors (AIs) compared with tamoxifen either as initial monotherapy (cohort 1) or after 2 to 3 years of tamoxifen (cohort 2).Data submitted to the Early Breast Cancer Trialists' Collaborative Group were used in separate meta-analyses of two cohorts. Primary analyses involve postmenopausal women with tumors reported to be estrogen receptor positive. Log-rank P values are two-sided.MATERIALS AND METHODSData submitted to the Early Breast Cancer Trialists' Collaborative Group were used in separate meta-analyses of two cohorts. Primary analyses involve postmenopausal women with tumors reported to be estrogen receptor positive. Log-rank P values are two-sided.Cohort 1 comprised 9,856 patients with a mean of 5.8 years of follow-up. At 5 years, AI therapy was associated with an absolute 2.9% (SE = 0.7%) decrease in recurrence (9.6% for AI v 12.6% for tamoxifen; 2P < .00001) and a nonsignificant absolute 1.1% (SE = 0.5%) decrease in breast cancer mortality (4.8% for AI v 5.9% for tamoxifen; 2P = .1). Cohort 2 comprised 9,015 patients with a mean of 3.9 years of follow-up. At 3 years from treatment divergence (ie, approximately 5 years after starting hormonal treatment), AI therapy was associated with an absolute 3.1% (SE = 0.6%) decrease in recurrence (5.0% for AI v 8.1% for tamoxifen since divergence; 2P < .00001) and an absolute 0.7% (SE = 0.3%) decrease in breast cancer mortality (1.7% for AI v 2.4% for tamoxifen since divergence; 2P = .02). There was no convincing heterogeneity in the proportional recurrence reduction with respect to age, nodal status, tumor grade, or progesterone receptor status and no indication of an increase in nonbreast deaths with AIs in either cohort. CONCLUSION AIs produce significantly lower recurrence rates compared with tamoxifen, either as initial monotherapy or after 2 to 3 years of tamoxifen. Additional follow-up will provide clearer information on long-term survival.RESULTSCohort 1 comprised 9,856 patients with a mean of 5.8 years of follow-up. At 5 years, AI therapy was associated with an absolute 2.9% (SE = 0.7%) decrease in recurrence (9.6% for AI v 12.6% for tamoxifen; 2P < .00001) and a nonsignificant absolute 1.1% (SE = 0.5%) decrease in breast cancer mortality (4.8% for AI v 5.9% for tamoxifen; 2P = .1). Cohort 2 comprised 9,015 patients with a mean of 3.9 years of follow-up. At 3 years from treatment divergence (ie, approximately 5 years after starting hormonal treatment), AI therapy was associated with an absolute 3.1% (SE = 0.6%) decrease in recurrence (5.0% for AI v 8.1% for tamoxifen since divergence; 2P < .00001) and an absolute 0.7% (SE = 0.3%) decrease in breast cancer mortality (1.7% for AI v 2.4% for tamoxifen since divergence; 2P = .02). There was no convincing heterogeneity in the proportional recurrence reduction with respect to age, nodal status, tumor grade, or progesterone receptor status and no indication of an increase in nonbreast deaths with AIs in either cohort. CONCLUSION AIs produce significantly lower recurrence rates compared with tamoxifen, either as initial monotherapy or after 2 to 3 years of tamoxifen. Additional follow-up will provide clearer information on long-term survival.
Author	Snowdon, Claire Coates, Alan Dowsett, Mitch Cuzick, Jack Forbes, John Buzdar, Aman Coombes, Charles Baum, Michael Buyse, Marc Peto, Richard Bliss, Judith Boccardo, Francesco Davies, Christina Ingle, Jim Gnant, Michael Colleoni, Marco Jakesz, Raimund Kaufmann, Manfred Godwin, Jon
Author_xml	– sequence: 1 givenname: Mitch surname: Dowsett fullname: Dowsett, Mitch email: mitch.dowsett@icr.ac.uk organization: Academic Department of Biochemistry, Royal Marsden Hospital, London, United Kingdom. mitch.dowsett@icr.ac.uk – sequence: 2 givenname: Jack surname: Cuzick fullname: Cuzick, Jack – sequence: 3 givenname: Jim surname: Ingle fullname: Ingle, Jim – sequence: 4 givenname: Alan surname: Coates fullname: Coates, Alan – sequence: 5 givenname: John surname: Forbes fullname: Forbes, John – sequence: 6 givenname: Judith surname: Bliss fullname: Bliss, Judith – sequence: 7 givenname: Marc surname: Buyse fullname: Buyse, Marc – sequence: 8 givenname: Michael surname: Baum fullname: Baum, Michael – sequence: 9 givenname: Aman surname: Buzdar fullname: Buzdar, Aman – sequence: 10 givenname: Marco surname: Colleoni fullname: Colleoni, Marco – sequence: 11 givenname: Charles surname: Coombes fullname: Coombes, Charles – sequence: 12 givenname: Claire surname: Snowdon fullname: Snowdon, Claire – sequence: 13 givenname: Michael surname: Gnant fullname: Gnant, Michael – sequence: 14 givenname: Raimund surname: Jakesz fullname: Jakesz, Raimund – sequence: 15 givenname: Manfred surname: Kaufmann fullname: Kaufmann, Manfred – sequence: 16 givenname: Francesco surname: Boccardo fullname: Boccardo, Francesco – sequence: 17 givenname: Jon surname: Godwin fullname: Godwin, Jon – sequence: 18 givenname: Christina surname: Davies fullname: Davies, Christina – sequence: 19 givenname: Richard surname: Peto fullname: Peto, Richard
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/19949017$$D View this record in MEDLINE/PubMed
BookMark	eNpNkD1PwzAYhC1UREthZ0LemFLsOLaTEVV8qqgLzNEb541w1djFdir674mgSEx3unt0w52TifMOCbnibMFzxm5fluvFqNUiF2OgixMy4zLXmdZSTv75KTmPccMYL0ohz8iUV1VRMa5nxLxiggwcbA_RRuo72gSEmKgBZzBQPyTje4zUOgrtZtiDSzQFC9sfGILvIUHEsf-wjU0-RLrHEIdIE_T-y3boLshpN_J4edQ5eX-4f1s-Zav14_PybpWZQqmUqRxUJZQwvDNcGmnKkje8aJlSRjNojGIoTZtXHROskCKXHYoSmkKiASx1Pic3v7u74D8HjKnubTS43YJDP8RaC1FpVQo1ktdHcmh6bOtdsD2EQ_33S_4NNtFoRA
CitedBy_id	crossref_primary_10_1111_bcp_13130 crossref_primary_10_12688_f1000research_4340_1 crossref_primary_10_3389_fonc_2021_576007 crossref_primary_10_1016_j_jclinepi_2018_10_014 crossref_primary_10_1007_s10549_014_3130_4 crossref_primary_10_1016_j_diii_2014_04_003 crossref_primary_10_1007_s10549_024_07519_z crossref_primary_10_1016_j_clbc_2021_01_006 crossref_primary_10_1007_s10549_016_3892_y crossref_primary_10_1007_s12672_016_0259_0 crossref_primary_10_1634_theoncologist_2011_S1_40 crossref_primary_10_1016_S1470_2045_10_70270_9 crossref_primary_10_1200_JCO_2011_36_8993 crossref_primary_10_1016_j_mgene_2019_100596 crossref_primary_10_1016_j_ejca_2014_08_011 crossref_primary_10_1200_JCO_2011_38_0261 crossref_primary_10_1016_j_ejca_2014_01_007 crossref_primary_10_1016_j_tem_2010_03_005 crossref_primary_10_1007_s15015_019_0168_5 crossref_primary_10_1016_j_breast_2013_09_006 crossref_primary_10_1200_JCO_2017_76_5719 crossref_primary_10_1016_j_clbc_2015_11_002 crossref_primary_10_1111_jcpt_12227 crossref_primary_10_1186_1471_2407_13_473 crossref_primary_10_1186_bcr3481 crossref_primary_10_14694_EdBook_AM_2012_32_87 crossref_primary_10_1016_j_pupt_2022_102128 crossref_primary_10_1016_j_pharmthera_2017_12_012 crossref_primary_10_1016_S1359_6349_11_70008_8 crossref_primary_10_1016_j_clbc_2014_02_003 crossref_primary_10_1016_j_breast_2013_01_007 crossref_primary_10_1038_jhg_2013_35 crossref_primary_10_1007_s00404_017_4572_9 crossref_primary_10_1016_j_mce_2015_09_035 crossref_primary_10_1200_JCO_25_00371 crossref_primary_10_1002_path_6157 crossref_primary_10_1186_2193_1801_2_5 crossref_primary_10_1016_j_ejso_2011_11_003 crossref_primary_10_1016_j_breast_2013_02_015 crossref_primary_10_1200_JCO_2017_74_8301 crossref_primary_10_1016_j_breast_2020_08_003 crossref_primary_10_1007_s10549_013_2767_8 crossref_primary_10_1016_j_radonc_2025_111054 crossref_primary_10_1016_S0140_6736_15_61074_1 crossref_primary_10_1007_s12094_013_1084_3 crossref_primary_10_1016_j_canlet_2015_07_017 crossref_primary_10_1016_S1470_2045_11_70323_0 crossref_primary_10_1002_cncr_28084 crossref_primary_10_1007_s00129_015_3802_0 crossref_primary_10_1038_onc_2013_78 crossref_primary_10_7759_cureus_37383 crossref_primary_10_1016_j_ctrv_2015_02_004 crossref_primary_10_1038_onc_2014_45 crossref_primary_10_1007_s10552_017_0937_4 crossref_primary_10_1016_S0140_6736_11_61625_5 crossref_primary_10_1200_JCO_2010_28_5338 crossref_primary_10_1007_s00109_014_1226_2 crossref_primary_10_1245_s10434_017_6021_1 crossref_primary_10_1080_14737140_2023_2162043 crossref_primary_10_1093_nop_npae057 crossref_primary_10_1007_s00774_023_01414_1 crossref_primary_10_1016_j_breast_2025_104429 crossref_primary_10_12771_emj_2014_37_2_83 crossref_primary_10_1186_1471_2407_14_172 crossref_primary_10_1093_annonc_mds075 crossref_primary_10_1586_14737167_2016_1159514 crossref_primary_10_1093_annonc_mdt284 crossref_primary_10_1016_j_ejca_2012_12_025 crossref_primary_10_1007_s10549_016_3807_y crossref_primary_10_1001_jamainternmed_2024_4224 crossref_primary_10_1007_s10549_017_4106_y crossref_primary_10_1186_s12874_022_01549_1 crossref_primary_10_1016_S0140_6736_12_62038_8 crossref_primary_10_1016_j_cpet_2018_02_007 crossref_primary_10_1200_JCO_2013_48_9153 crossref_primary_10_1038_s41523_018_0075_5 crossref_primary_10_1186_2193_1801_2_366 crossref_primary_10_1016_j_pharmthera_2013_03_001 crossref_primary_10_1093_annonc_mdw266 crossref_primary_10_1093_annonc_mdv298 crossref_primary_10_1016_j_critrevonc_2012_06_005 crossref_primary_10_1097_EDE_0b013e31828b0866 crossref_primary_10_1200_JCO_2011_38_3331 crossref_primary_10_1016_j_breast_2013_01_014 crossref_primary_10_1007_s11912_013_0358_9 crossref_primary_10_1007_s00520_014_2364_3 crossref_primary_10_1136_bmjopen_2014_005285 crossref_primary_10_1007_s10549_014_3140_2 crossref_primary_10_1002_jso_21842 crossref_primary_10_1200_JCO_2010_33_7899 crossref_primary_10_1007_s00129_011_2919_z crossref_primary_10_1200_JCO_2012_47_2167 crossref_primary_10_1111_bph_12864 crossref_primary_10_1002_cncr_27818 crossref_primary_10_1016_j_breast_2018_10_007 crossref_primary_10_1016_j_ctrv_2016_03_004 crossref_primary_10_1016_j_breast_2016_01_006 crossref_primary_10_1016_j_maturitas_2011_09_006 crossref_primary_10_1210_endocr_bqaa177 crossref_primary_10_1016_S1470_2045_13_70589_8 crossref_primary_10_2217_WHE_10_25 crossref_primary_10_1016_j_jpain_2014_01_487 crossref_primary_10_1007_s00198_011_1870_0 crossref_primary_10_1042_EBC20200174 crossref_primary_10_1038_bjc_2016_276 crossref_primary_10_1007_s40266_020_00748_z crossref_primary_10_1093_annonc_mdv392 crossref_primary_10_1007_s10555_010_9248_x crossref_primary_10_1007_s10549_012_2032_6 crossref_primary_10_1016_j_ejogrb_2024_01_021 crossref_primary_10_1016_j_jsbmb_2017_07_001 crossref_primary_10_1016_j_esmoop_2025_105057 crossref_primary_10_1056_NEJMoa1103507 crossref_primary_10_1210_endrev_bnab028 crossref_primary_10_1007_s10549_010_1072_z crossref_primary_10_1007_s12609_014_0144_1 crossref_primary_10_1016_j_breastdis_2011_01_023 crossref_primary_10_1016_j_senol_2025_100683 crossref_primary_10_1177_1933719113503408 crossref_primary_10_1016_S0140_6736_12_61963_1 crossref_primary_10_1007_s10269_013_2344_4 crossref_primary_10_2188_jea_JE20170103 crossref_primary_10_1146_annurev_med_043015_075227 crossref_primary_10_1016_S0140_6736_22_01977_8 crossref_primary_10_1517_14740338_2014_955848 crossref_primary_10_1007_s12325_011_0017_1 crossref_primary_10_1097_GME_0b013e31827ce094 crossref_primary_10_1111_joim_12429 crossref_primary_10_1007_s11912_012_0273_5 crossref_primary_10_1016_j_breast_2013_07_017 crossref_primary_10_1177_11782234221145440 crossref_primary_10_1007_s00774_018_0917_0 crossref_primary_10_1093_aje_kwu189 crossref_primary_10_2217_cer_2019_0168 crossref_primary_10_1002_sm2_22 crossref_primary_10_1016_j_breast_2023_05_007 crossref_primary_10_3390_cancers12102918 crossref_primary_10_1186_s12905_016_0361_z crossref_primary_10_1097_01_med_0000436195_10599_dd crossref_primary_10_1186_1471_2407_14_467 crossref_primary_10_1200_JCO_2009_26_3756 crossref_primary_10_1097_MLR_0000000000000685 crossref_primary_10_1007_s11864_013_0263_3 crossref_primary_10_1007_s10549_021_06226_3 crossref_primary_10_1007_s00285_022_01729_z crossref_primary_10_1016_j_hoc_2013_05_011 crossref_primary_10_1016_j_breast_2013_07_033 crossref_primary_10_1177_2053369116685452 crossref_primary_10_3390_ph3041122 crossref_primary_10_1002_adhm_202300103 crossref_primary_10_1007_s11912_020_00958_z crossref_primary_10_1038_s41598_021_83628_9 crossref_primary_10_1016_S1470_2045_14_70050_6 crossref_primary_10_1053_j_seminoncol_2020_05_010 crossref_primary_10_1684_bdc_2011_1367 crossref_primary_10_1371_journal_pone_0055355 crossref_primary_10_1186_1471_2407_13_426 crossref_primary_10_1016_S1470_2045_17_30536_3 crossref_primary_10_1007_s10549_015_3608_8 crossref_primary_10_1158_1940_6207_CAPR_17_0162 crossref_primary_10_1016_j_clbc_2022_09_007 crossref_primary_10_1111_hex_12178 crossref_primary_10_1177_0091270011424153 crossref_primary_10_1111_cas_15734 crossref_primary_10_1016_j_bjps_2017_05_046 crossref_primary_10_1093_annonc_mdr017 crossref_primary_10_1016_j_breast_2013_07_035 crossref_primary_10_1158_1078_0432_CCR_12_2789 crossref_primary_10_3390_cancers7030833 crossref_primary_10_1016_j_soc_2010_03_006 crossref_primary_10_1007_s10549_023_07218_1 crossref_primary_10_1016_j_mayocp_2013_12_014 crossref_primary_10_1007_s15013_019_1574_7 crossref_primary_10_1056_NEJMoa1412379 crossref_primary_10_1097_PRS_0000000000004359 crossref_primary_10_1016_S1470_2045_11_70373_4 crossref_primary_10_1158_1078_0432_CCR_15_1213 crossref_primary_10_1007_s12254_012_0027_y crossref_primary_10_1177_0272989X17737508 crossref_primary_10_1093_jncics_pkz062 crossref_primary_10_1016_j_jddst_2022_103655 crossref_primary_10_1371_journal_pone_0311044 crossref_primary_10_3390_jcm7090287 crossref_primary_10_1007_s10549_012_2023_7 crossref_primary_10_1186_s12905_022_01722_0 crossref_primary_10_1093_annonc_mdt149 crossref_primary_10_1530_ERC_17_0416 crossref_primary_10_1007_s10549_010_1223_2 crossref_primary_10_1016_j_jclinepi_2018_05_025 crossref_primary_10_1016_j_clbc_2014_06_005 crossref_primary_10_1016_S1470_2045_10_70257_6 crossref_primary_10_1159_000360702 crossref_primary_10_1186_s40199_014_0083_4 crossref_primary_10_1002_cncr_28756 crossref_primary_10_1186_s13058_014_0429_3 crossref_primary_10_14694_EdBook_AM_2015_35_48 crossref_primary_10_1007_s10549_012_1961_4 crossref_primary_10_1016_S0049_3848_19_30367_6 crossref_primary_10_1038_bjc_2013_707 crossref_primary_10_1200_JCO_2012_45_2615 crossref_primary_10_1016_j_soc_2012_12_005 crossref_primary_10_1016_j_jbo_2023_100501 crossref_primary_10_1016_j_ejca_2013_05_006 crossref_primary_10_1016_j_ctrv_2012_03_007 crossref_primary_10_1016_j_ejca_2013_10_001 crossref_primary_10_1016_j_bcp_2024_116178 crossref_primary_10_1007_s00761_013_2427_y crossref_primary_10_1016_S1470_2045_11_70399_0 crossref_primary_10_1007_s10689_011_9484_4 crossref_primary_10_1016_j_tox_2019_03_014 crossref_primary_10_1158_1078_0432_CCR_15_1470 crossref_primary_10_1016_j_ejca_2025_115665 crossref_primary_10_1177_030089161209800101 crossref_primary_10_3390_jcm7090245 crossref_primary_10_1007_s10549_020_05564_y crossref_primary_10_1188_17_ONF_E101_E110 crossref_primary_10_1080_10408398_2014_887057 crossref_primary_10_1200_EDBK_159069 crossref_primary_10_1245_s10434_015_4405_7 crossref_primary_10_1073_pnas_1103125108 crossref_primary_10_1016_j_canrad_2010_07_634 crossref_primary_10_3390_medicina60081268 crossref_primary_10_3892_ijo_2015_2850 crossref_primary_10_1093_annonc_mdt352 crossref_primary_10_7554_eLife_15828 crossref_primary_10_1016_j_ijrobp_2023_07_018 crossref_primary_10_1007_s12282_022_01383_9 crossref_primary_10_1093_jncics_pkab087 crossref_primary_10_3109_13697137_2013_819327 crossref_primary_10_1200_JCO_2011_36_3895 crossref_primary_10_1016_j_ctrv_2017_02_005 crossref_primary_10_1111_bjhp_12003 crossref_primary_10_1200_JCO_2012_42_8896 crossref_primary_10_2147_DDDT_S524181 crossref_primary_10_1016_j_ejca_2017_03_033 crossref_primary_10_1097_GME_0b013e3182955b77 crossref_primary_10_1128_MCB_06073_11 crossref_primary_10_1007_s12282_019_01013_x crossref_primary_10_1038_s41523_020_00212_6 crossref_primary_10_1016_j_jsbmb_2015_06_014 crossref_primary_10_1093_annonc_mdq596 crossref_primary_10_1007_s10549_018_4811_1 crossref_primary_10_1016_j_biopha_2018_06_105 crossref_primary_10_1200_JCO_2012_44_7805 crossref_primary_10_1200_JCO_2014_55_3073 crossref_primary_10_1177_2055102917740469 crossref_primary_10_1007_s10549_019_05201_3 crossref_primary_10_1093_annonc_mdz173 crossref_primary_10_2217_fon_2019_0254 crossref_primary_10_1016_j_jsxm_2021_12_010 crossref_primary_10_1097_GME_0000000000000426 crossref_primary_10_1016_j_reumae_2017_08_007 crossref_primary_10_1038_s41370_023_00601_6 crossref_primary_10_1038_onc_2016_397 crossref_primary_10_1007_s10549_018_4713_2 crossref_primary_10_1158_1078_0432_CCR_15_0296 crossref_primary_10_1007_s12282_017_0794_8 crossref_primary_10_1016_S0140_6736_10_62312_4 crossref_primary_10_3390_jcm2030151 crossref_primary_10_1016_j_clbc_2023_01_012 crossref_primary_10_1111_j_1445_5994_2010_02422_x crossref_primary_10_1186_bcr2837 crossref_primary_10_36290_xon_2018_048 crossref_primary_10_1016_j_steroids_2014_06_002 crossref_primary_10_1016_j_steroids_2014_06_003 crossref_primary_10_1016_S1470_2045_11_70141_3 crossref_primary_10_1188_20_CJON_139_147 crossref_primary_10_1097_GCO_0000000000000153 crossref_primary_10_1177_1359105321990776 crossref_primary_10_1016_j_taap_2023_116407 crossref_primary_10_1186_bcr2827 crossref_primary_10_1080_14737140_2016_1192466 crossref_primary_10_1093_annonc_mdq337 crossref_primary_10_1097_GCO_0000000000000039 crossref_primary_10_1016_j_gamo_2015_11_001 crossref_primary_10_1007_s12307_013_0139_x crossref_primary_10_2147_BCTT_S432526 crossref_primary_10_1158_1940_6207_CAPR_22_0106 crossref_primary_10_1007_s10549_012_2363_3 crossref_primary_10_1158_1078_0432_CCR_12_2153 crossref_primary_10_1186_s12955_019_1090_4 crossref_primary_10_1007_s10549_017_4501_4 crossref_primary_10_1073_pnas_1115188108 crossref_primary_10_1186_1477_7819_12_352 crossref_primary_10_1007_s00432_013_1557_3 crossref_primary_10_1016_j_clbc_2013_12_010 crossref_primary_10_1038_bjc_2013_587 crossref_primary_10_1007_s10549_017_4427_x crossref_primary_10_1155_2014_390618 crossref_primary_10_1016_j_ctrv_2017_01_005 crossref_primary_10_1177_1078155212474047 crossref_primary_10_1200_JCO_2010_34_3202 crossref_primary_10_1002_cam4_6937 crossref_primary_10_1016_j_bcp_2020_113850 crossref_primary_10_1016_j_yexmp_2020_104574 crossref_primary_10_1016_S0140_6736_13_62292_8 crossref_primary_10_1007_s00280_013_2195_9 crossref_primary_10_1007_s00761_012_2303_1 crossref_primary_10_1016_j_critrevonc_2011_09_002 crossref_primary_10_1136_postgradmedj_2016_134417 crossref_primary_10_1002_cpt_2904 crossref_primary_10_1007_s12013_014_0145_8 crossref_primary_10_1158_1541_7786_MCR_14_0128_T crossref_primary_10_1016_j_ando_2014_04_012 crossref_primary_10_1007_s12282_018_0871_7 crossref_primary_10_1158_1078_0432_CCR_14_2842 crossref_primary_10_1097_CCO_0000000000000323 crossref_primary_10_2217_fon_2016_0186 crossref_primary_10_1016_j_thromres_2019_02_019 crossref_primary_10_1097_PRS_0000000000001127 crossref_primary_10_1016_j_clbc_2017_03_002 crossref_primary_10_1016_S0960_9776_19_31125_7 crossref_primary_10_1093_annonc_mds330 crossref_primary_10_1158_2159_8290_CD_11_0248 crossref_primary_10_3390_cancers17020200 crossref_primary_10_1007_s10552_017_0888_9 crossref_primary_10_1371_journal_pone_0062614 crossref_primary_10_2217_bmt_15_2 crossref_primary_10_1016_j_ctrv_2016_08_008 crossref_primary_10_1007_s00432_015_2025_z crossref_primary_10_1038_nrclinonc_2013_17 crossref_primary_10_1245_s10434_023_14407_1 crossref_primary_10_1159_000440944 crossref_primary_10_3109_19390211_2014_952863 crossref_primary_10_1517_14656566_2010_487863 crossref_primary_10_1093_annonc_mdq281 crossref_primary_10_1093_annonc_mdr371 crossref_primary_10_1186_s12916_015_0373_9 crossref_primary_10_14423_SMJ_0000000000000703 crossref_primary_10_1007_s10552_024_01900_5 crossref_primary_10_1200_JCO_2014_57_2461 crossref_primary_10_1002_cpdd_420 crossref_primary_10_3390_diagnostics14232699 crossref_primary_10_1517_14740338_2010_515977 crossref_primary_10_1007_s10549_017_4177_9 crossref_primary_10_1371_journal_pone_0100159 crossref_primary_10_2217_bmt_12_34 crossref_primary_10_3390_nu16162644 crossref_primary_10_2217_whe_15_92 crossref_primary_10_3390_cancers13061219 crossref_primary_10_3390_cancers13092254 crossref_primary_10_1016_j_critrevonc_2017_04_008 crossref_primary_10_1155_2016_1381695 crossref_primary_10_1200_JCO_2010_31_6455 crossref_primary_10_1159_000477956 crossref_primary_10_1002_cam4_4949 crossref_primary_10_1517_13543784_2015_1008132 crossref_primary_10_1016_j_ejcsup_2013_07_029 crossref_primary_10_1016_j_ejca_2016_08_022 crossref_primary_10_1016_j_cger_2015_08_011 crossref_primary_10_1007_s12609_017_0255_6 crossref_primary_10_1080_15376516_2021_1934765 crossref_primary_10_5493_wjem_v8_i1_1 crossref_primary_10_1016_j_intimp_2019_05_003 crossref_primary_10_1093_jnci_djv075 crossref_primary_10_1016_j_jpainsymman_2016_03_010 crossref_primary_10_1016_S1470_2045_21_00758_0 crossref_primary_10_1038_nrclinonc_2013_174 crossref_primary_10_1080_09513590_2017_1318373 crossref_primary_10_1186_1471_2407_14_935 crossref_primary_10_1093_annonc_mds305 crossref_primary_10_1155_2018_6074808 crossref_primary_10_1007_s40487_018_0062_x crossref_primary_10_1016_j_canrad_2015_02_015 crossref_primary_10_1177_10781552231167559 crossref_primary_10_1038_s41598_022_26954_w crossref_primary_10_3389_fonc_2021_798296 crossref_primary_10_1016_S0140_6736_11_61128_8 crossref_primary_10_1016_j_mce_2013_08_001 crossref_primary_10_1016_S0140_6736_11_60993_8 crossref_primary_10_1371_journal_pone_0111477 crossref_primary_10_1188_12_CJON_260_266 crossref_primary_10_1016_j_critrevonc_2012_09_013 crossref_primary_10_1016_S0140_6736_16_31891_8 crossref_primary_10_1038_bjc_2016_174 crossref_primary_10_1093_annonc_mdq754 crossref_primary_10_1093_annonc_mdr600 crossref_primary_10_1007_s10552_018_1042_z crossref_primary_10_1016_j_maturitas_2014_12_005 crossref_primary_10_1038_s41523_019_0118_6 crossref_primary_10_1200_JGO_19_00408 crossref_primary_10_1038_s41523_017_0035_5 crossref_primary_10_1007_s00520_025_09257_4 crossref_primary_10_1080_01635581_2014_847964 crossref_primary_10_1188_16_ONF_E143_E152 crossref_primary_10_1007_s10549_016_3811_2 crossref_primary_10_1016_j_suc_2018_04_002 crossref_primary_10_1210_clinem_dgaa463 crossref_primary_10_1056_NEJMe1106052 crossref_primary_10_1111_tbj_12783 crossref_primary_10_1038_s41598_020_61093_0 crossref_primary_10_1016_j_mce_2015_06_004 crossref_primary_10_1055_s_0044_1786517 crossref_primary_10_1007_s10549_012_1968_x crossref_primary_10_1634_theoncologist_2010_S5_18 crossref_primary_10_3390_ijerph17103692 crossref_primary_10_3892_ol_2017_6298 crossref_primary_10_1016_j_jradio_2014_03_011 crossref_primary_10_1186_s13167_015_0037_z crossref_primary_10_1200_JCO_2011_38_6888 crossref_primary_10_1634_theoncologist_2011_0418 crossref_primary_10_1007_s10549_018_4936_2 crossref_primary_10_3109_13697137_2014_996749 crossref_primary_10_2217_ahe_10_42 crossref_primary_10_3390_cancers16020426 crossref_primary_10_1007_s11912_020_01000_y crossref_primary_10_2217_bmt_14_10 crossref_primary_10_5306_wjco_v5_i3_359 crossref_primary_10_1002_jcp_22920 crossref_primary_10_1200_JCO_2016_70_9386 crossref_primary_10_1016_j_steroids_2014_08_008 crossref_primary_10_1200_JCO_2012_46_6599 crossref_primary_10_1111_jog_13980 crossref_primary_10_1007_s10549_017_4626_5 crossref_primary_10_1097_COC_0000000000000351 crossref_primary_10_1016_S1470_2045_11_70270_4 crossref_primary_10_1016_j_ctarc_2021_100358 crossref_primary_10_1093_annonc_mdq738 crossref_primary_10_31362_patd_1621040 crossref_primary_10_1136_heartjnl_2020_317510 crossref_primary_10_1016_j_eururo_2013_09_007 crossref_primary_10_3390_cancers14215206 crossref_primary_10_1177_1078155218762626 crossref_primary_10_1016_j_steroids_2014_08_007 crossref_primary_10_1093_annonc_mdv193 crossref_primary_10_1245_s10434_015_4487_2 crossref_primary_10_1186_s40064_015_1096_2 crossref_primary_10_1016_j_mce_2013_03_025 crossref_primary_10_1016_j_breast_2015_07_002 crossref_primary_10_1093_jnci_djr242 crossref_primary_10_1016_j_bulcan_2015_10_011 crossref_primary_10_1016_j_steroids_2014_12_013 crossref_primary_10_1200_JCO_2015_63_4972 crossref_primary_10_1016_S1470_2045_11_70328_X crossref_primary_10_1007_s13691_014_0164_8 crossref_primary_10_1038_s41523_016_0003_5 crossref_primary_10_1038_tpj_2016_73 crossref_primary_10_1016_j_mce_2021_111284 crossref_primary_10_1089_jwh_2014_4982 crossref_primary_10_1016_S1470_2045_14_70035_X crossref_primary_10_2217_WHE_15_2 crossref_primary_10_1586_era_11_13 crossref_primary_10_1038_nrclinonc_2013_124 crossref_primary_10_3109_13697137_2015_1100383 crossref_primary_10_1007_s11864_012_0213_5 crossref_primary_10_1177_1758834015608993 crossref_primary_10_1016_j_canlet_2018_10_041 crossref_primary_10_1177_1043659618771475 crossref_primary_10_1007_s10549_011_1351_3 crossref_primary_10_1016_j_steroids_2011_02_032 crossref_primary_10_1007_s10549_014_2935_5 crossref_primary_10_1016_j_breast_2011_08_001 crossref_primary_10_1007_s13126_016_0326_6 crossref_primary_10_1177_0969141314549368 crossref_primary_10_1200_JCO_2010_28_3564 crossref_primary_10_1016_j_breast_2020_06_012 crossref_primary_10_1016_j_mam_2014_12_003 crossref_primary_10_1007_s00129_012_3007_8 crossref_primary_10_1038_s41588_023_01507_7 crossref_primary_10_3390_cancers15112872 crossref_primary_10_4137_CMWH_S8692 crossref_primary_10_1186_bcr3609 crossref_primary_10_1016_j_clbc_2017_12_002 crossref_primary_10_1016_j_phrs_2017_07_015 crossref_primary_10_1093_annonc_mdq541 crossref_primary_10_1007_s10549_012_2207_1 crossref_primary_10_1016_j_ejso_2019_12_026 crossref_primary_10_1038_nrclinonc_2015_147 crossref_primary_10_1016_S0140_6736_11_60073_1 crossref_primary_10_1007_s12609_017_0248_5 crossref_primary_10_1111_j_1524_4741_2012_01246_x crossref_primary_10_1038_bjc_2011_441 crossref_primary_10_2217_bmt_15_29 crossref_primary_10_1007_s12010_020_03388_6 crossref_primary_10_1038_bonekey_2015_60 crossref_primary_10_1007_s12032_010_9516_1 crossref_primary_10_1007_s10549_017_4494_z crossref_primary_10_1093_jnci_djr302 crossref_primary_10_1016_j_jcpo_2014_01_002 crossref_primary_10_1007_s10549_013_2504_3 crossref_primary_10_1093_annonc_mdq774 crossref_primary_10_1186_s40064_015_0827_8 crossref_primary_10_1007_s11764_019_00782_w crossref_primary_10_1016_j_molonc_2012_02_003 crossref_primary_10_1007_s10549_011_1703_z crossref_primary_10_1007_s10549_019_05501_8 crossref_primary_10_1007_s00520_021_06180_2 crossref_primary_10_1016_j_breast_2015_07_027 crossref_primary_10_1007_s12325_021_01924_2 crossref_primary_10_2147_PGPM_S308531 crossref_primary_10_1245_s10434_011_2070_z crossref_primary_10_1186_s12885_025_14280_z crossref_primary_10_3109_07357907_2014_880452 crossref_primary_10_2217_pgs_13_221 crossref_primary_10_1016_j_cmonc_2012_02_005 crossref_primary_10_1007_s13277_015_4440_9 crossref_primary_10_1210_en_2012_1353 crossref_primary_10_1007_s10549_015_3647_1 crossref_primary_10_1186_s13058_021_01464_1 crossref_primary_10_2217_fon_2017_0228 crossref_primary_10_3389_fonc_2022_859838 crossref_primary_10_1038_bonekey_2012_201 crossref_primary_10_1016_j_currproblcancer_2025_101235 crossref_primary_10_1007_s10549_013_2648_1 crossref_primary_10_2147_BCTT_S284453 crossref_primary_10_1200_JCO_2010_33_2585 crossref_primary_10_4331_wjbc_v6_i3_231 crossref_primary_10_2217_pgs_2017_0006 crossref_primary_10_1016_j_steroids_2011_02_021 crossref_primary_10_1016_j_surge_2013_11_021 crossref_primary_10_1001_jamanetworkopen_2023_50950 crossref_primary_10_1038_onc_2011_627 crossref_primary_10_1016_j_ctrv_2012_07_006 crossref_primary_10_3390_cancers11122027
ContentType	Journal Article
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1200/JCO.2009.23.1274
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine Pharmacy, Therapeutics, & Pharmacology
EISSN	1527-7755
ExternalDocumentID	19949017
Genre	Meta-Analysis Comparative Study Research Support, Non-U.S. Gov't Journal Article
GrantInformation_xml	– fundername: Breast Cancer Now grantid: BREAST CANCER NOW RESEARCH CENTRE – fundername: Medical Research Council grantid: MC_U137686850
GroupedDBID	--- .55 0R~ 18M 2WC 34G 39C 3O- 4.4 53G 5GY 5RE 8F7 AARDX AAWTL AAYEP ABBLC ABJNI ABOCM ACGFO ACGFS ACGUR ADBBV AEGXH AENEX AFFNX AI. AIAGR ALMA_UNASSIGNED_HOLDINGS BAWUL C45 CGR CS3 CUY CVF DIK EBS ECM EIF EJD F5P F9R FBNNL FD8 GX1 H13 HZ~ IH2 KQ8 L7B LSO MJL N4W N9A NPM O9- OK1 OVD OWW P2P QTD R1G RHI RLZ RUC SJN TEORI TR2 TWZ UDS VH1 VVN WH7 X7M YFH YQY 7X8
ID	FETCH-LOGICAL-c466t-62a69363c1fc15c5c881b14d066c70abc60e5cd29f03045325fe38ab45ecae872
IEDL.DBID	7X8
ISICitedReferencesCount	641
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000273662700023&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1527-7755
IngestDate	Fri Sep 05 12:30:55 EDT 2025 Mon Jul 21 06:01:13 EDT 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	3
Language	English
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c466t-62a69363c1fc15c5c881b14d066c70abc60e5cd29f03045325fe38ab45ecae872
Notes	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23
OpenAccessLink	https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2009.23.1274?role=tab
PMID	19949017
PQID	733976836
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_733976836 pubmed_primary_19949017
PublicationCentury	2000
PublicationDate	2010-01-20
PublicationDateYYYYMMDD	2010-01-20
PublicationDate_xml	– month: 01 year: 2010 text: 2010-01-20 day: 20
PublicationDecade	2010
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	Journal of clinical oncology
PublicationTitleAlternate	J Clin Oncol
PublicationYear	2010
References	20458046 - J Clin Oncol. 2010 Jul 10;28(20):e346-7; author reply e348. doi: 10.1200/JCO.2010.28.3564.
References_xml	– reference: 20458046 - J Clin Oncol. 2010 Jul 10;28(20):e346-7; author reply e348. doi: 10.1200/JCO.2010.28.3564.
SSID	ssj0014835
Score	2.5420523
SecondaryResourceType	review_article
Snippet	To conduct meta-analyses of randomized trials of aromatase inhibitors (AIs) compared with tamoxifen either as initial monotherapy (cohort 1) or after 2 to 3...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	509
SubjectTerms	Aged Antineoplastic Agents - therapeutic use Aromatase Inhibitors - therapeutic use Breast Neoplasms - drug therapy Breast Neoplasms - surgery Chemotherapy, Adjuvant Female Follow-Up Studies Humans Middle Aged Randomized Controlled Trials as Topic Tamoxifen - therapeutic use
Title	Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen
URI	https://www.ncbi.nlm.nih.gov/pubmed/19949017 https://www.proquest.com/docview/733976836
Volume	28
WOSCitedRecordID	wos000273662700023&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEF7UinjxUV_1xR6kp4aabLLZnESKRYTWHCr0VjaTXYxgUptE7L93NkntSTx4ySHJwrLzMfNNZjIfITcIAhG5wDAtUcxCfhtZkivb8rXrKQ9spaNabMIfj8V0GoRNb07etFWufGLlqOMMzDfyvs9M5BSM380_LCMaZYqrjYLGJmkxZDIG1P50XURwRaWvaYRbkUR6XlOlRFz0nwbP9axKh-EN0-33G7-s4sxw_587PCB7DcGk9zUiDsmGSttkZ9SU0NukG9bDqpc9Oln_e5X3aJeG6zHWyyMCI1VISzZDS2imaWQa2AsKBigLmpUF7kvlNEmpjN9KpOQFrURAqpflIkMyjDESn78mUWJUfajpASlzWsj37CvRKj0mL8OHyeDRaiQZLHA5LyzuSB4wzsDWYHvggUDaa7sxEhfwb2UE_BYtHDuBrkqwzPG0YkJGaHiQSvjOCdlKs1SdEcokBEpgvhQzjKSCR7bG9ZIBgwCzZq9D6OqYZwh5U8eQqcrKfPZz0B1yWptqNq9Hc8zMpGNkOP7534svyG7dCWCjp7gkLY3Ho67INnwWSb64rqCE13E4-gaGQdUD
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Meta-analysis+of+breast+cancer+outcomes+in+adjuvant+trials+of+aromatase+inhibitors+versus+tamoxifen&rft.jtitle=Journal+of+clinical+oncology&rft.au=Dowsett%2C+Mitch&rft.au=Cuzick%2C+Jack&rft.au=Ingle%2C+Jim&rft.au=Coates%2C+Alan&rft.date=2010-01-20&rft.issn=1527-7755&rft.eissn=1527-7755&rft.volume=28&rft.issue=3&rft.spage=509&rft_id=info:doi/10.1200%2FJCO.2009.23.1274&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1527-7755&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1527-7755&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1527-7755&client=summon